7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Hypertension, Pulmonary D006976 32 associated lipids
Hypertension D006973 115 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Hyperparathyroidism D006961 3 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hypercalcemia D006934 13 associated lipids
Hyperalgesia D006930 42 associated lipids
HIV Seropositivity D006679 15 associated lipids
Histiocytosis, Langerhans-Cell D006646 1 associated lipids
Hirsutism D006628 3 associated lipids
Hip Fractures D006620 2 associated lipids
Hip Dislocation D006617 1 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hepatitis C D006526 7 associated lipids
Hemophilia A D006467 10 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Hemarthrosis D006395 1 associated lipids
Heart Valve Diseases D006349 4 associated lipids
Heart Failure D006333 36 associated lipids
Graves Disease D006111 6 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Glioma D005910 112 associated lipids
Gingival Recession D005889 2 associated lipids
Foreign-Body Reaction D005549 10 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Eye Neoplasms D005134 2 associated lipids
Endometriosis D004715 29 associated lipids
Endocrine System Diseases D004700 4 associated lipids
Encephalitis D004660 15 associated lipids
Emphysema D004646 1 associated lipids
Disease Susceptibility D004198 12 associated lipids
Dilatation, Pathologic D004108 5 associated lipids
Diarrhea D003967 32 associated lipids
Diabetic Neuropathies D003929 5 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Dermatomyositis D003882 2 associated lipids
Dentin Dysplasia D003805 1 associated lipids
Dental Pulp Necrosis D003790 6 associated lipids
Dental Pulp Exposure D003789 1 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dental Occlusion, Traumatic D003769 1 associated lipids
Dengue D003715 2 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cryptosporidiosis D003457 3 associated lipids
Crohn Disease D003424 12 associated lipids
Coronary Disease D003327 70 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Cleidocranial Dysplasia D002973 1 associated lipids
Chronic Disease D002908 7 associated lipids
Chondrocalcinosis D002805 1 associated lipids
Chondroblastoma D002804 1 associated lipids
Cherubism D002636 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Celiac Disease D002446 16 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carcinosarcoma D002296 7 associated lipids
Carcinoma, Papillary D002291 3 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Carcinoma D002277 18 associated lipids
Carcinoid Heart Disease D002275 1 associated lipids
Calcinosis D002114 5 associated lipids
Cachexia D002100 21 associated lipids
Bone Resorption D001862 7 associated lipids
Bone Neoplasms D001859 5 associated lipids
Bone Diseases, Metabolic D001851 9 associated lipids
Bone Diseases, Endocrine D001849 1 associated lipids
Bone Diseases, Developmental D001848 2 associated lipids
Body Weight D001835 333 associated lipids
Biliary Atresia D001656 4 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Arthropathy, Neurogenic D001177 1 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis D001168 41 associated lipids
Arteriosclerosis D001161 86 associated lipids
Aortic Diseases D001018 11 associated lipids
Ankylosis D000844 1 associated lipids
Angioid Streaks D000793 1 associated lipids
Angina, Unstable D000789 14 associated lipids
Alzheimer Disease D000544 76 associated lipids
Albuminuria D000419 18 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Adenocarcinoma D000230 166 associated lipids
Addison Disease D000224 3 associated lipids
Actinomycosis D000196 2 associated lipids
Actinobacillus Infections D000189 4 associated lipids
Acromegaly D000172 6 associated lipids
Vestibulocochlear Nerve Diseases D000160 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Cundy T et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. 2002 Hum. Mol. Genet. pmid:12189164
Williamson E et al. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. 2002 J. Immunol. pmid:12244151
Lee SK et al. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. 2002 J. Immunol. pmid:12193704
Ferrer Cañabate J et al. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?]. 2002 An Med Interna pmid:12244784
Chen XW et al. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. 2002 Biochem. Biophys. Res. Commun. pmid:12150965
Katagiri T and Takahashi N Regulatory mechanisms of osteoblast and osteoclast differentiation. 2002 Oral Dis pmid:12108759
Lee SK and Lorenzo JA Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. 2002 Bone pmid:12110442
Shioi A et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. 2002 Circ. Res. pmid:12114316
Lipton A et al. Serum osteoprotegerin levels in healthy controls and cancer patients. 2002 Clin. Cancer Res. pmid:12114435
Fujita T et al. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. 2002 J. Oral Pathol. Med. pmid:12201246
Juji T et al. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. 2002 J. Bone Miner. Metab. pmid:12203031
Grisar J et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. 2002 J. Rheumatol. pmid:12136902
Hofbauer LC et al. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. 2002 Eur. J. Endocrinol. pmid:12153751
Mundy GR Metastasis to bone: causes, consequences and therapeutic opportunities. 2002 Nat. Rev. Cancer pmid:12154351
Lorget F et al. Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. 2002 Biochem. Biophys. Res. Commun. pmid:12163011
Ulrich-Vinther M et al. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. 2002 J Bone Joint Surg Am pmid:12177271
Ohmori H et al. Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. 2002 J. Hum. Genet. pmid:12181640
Armstrong AP et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. 2002 J. Biol. Chem. pmid:12185073
Schoppet M et al. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. 2002 Arterioscler. Thromb. Vasc. Biol. pmid:11950689
Hasegawa T et al. Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. 2002 Tissue Cell pmid:11989970
Evdokiou A et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. 2002 Int. J. Cancer pmid:11992538
Corey E et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. 2002 Prostate pmid:11992617
Gruber R et al. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. 2002 Bone pmid:11996911
de Hooge AS et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. 2002 Am. J. Pathol. pmid:12000725
Jiang Y et al. Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. 2002 Infect. Immun. pmid:12011008
Granchi D et al. Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. 2002 Biomaterials pmid:12013183
Li X et al. Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. 2002 Prostaglandins Other Lipid Mediat. pmid:12013525
Bosshart H Expression of survival receptors in Hodgkin disease cell lines. 2002 Blood pmid:12001908
Ono K et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. 2002 J. Bone Miner. Res. pmid:12009007
Iida-Klein A et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. 2002 J. Bone Miner. Res. pmid:12009011
Jain RG and Lenhard JM Select HIV protease inhibitors alter bone and fat metabolism ex vivo. 2002 J. Biol. Chem. pmid:11937496
Ariyasu T et al. Trehalose augments osteoprotegerin production in the FHs74Int human intestinal epithelial cell line. 2002 In Vitro Cell. Dev. Biol. Anim. pmid:11963965
Bateman TA and Countryman S Osteoprotegerin and bone loss associated with spaceflight. 2002 Drug Discov. Today pmid:11965392
Price PA et al. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. 2002 J. Bone Miner. Res. pmid:12096831
Xing L et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. 2002 J. Bone Miner. Res. pmid:12096833
Zou W and Bar-Shavit Z Dual modulation of osteoclast differentiation by lipopolysaccharide. 2002 J. Bone Miner. Res. pmid:12096834
Koyama H et al. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. 2002 J. Bone Miner. Res. pmid:12096835
Langdahl BL et al. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. 2002 J. Bone Miner. Res. pmid:12096838
Zhang J et al. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. 2002 J. Bone Miner. Res. pmid:12096839
Treuheit MJ et al. Inverse relationship of protein concentration and aggregation. 2002 Pharm. Res. pmid:12033388
Lossdörfer S et al. Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. 2002 Calcif. Tissue Int. pmid:12043011
Zhang J et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. 2002 FEBS Lett. pmid:12067713
Nakamura H et al. Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. 2002 J. Histochem. Cytochem. pmid:12070273
Brändström H et al. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. 2002 Biochem. Biophys. Res. Commun. pmid:12054556
Wittrant Y et al. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. 2002 Biochem. Biophys. Res. Commun. pmid:12054560
Fu Q et al. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. 2002 J. Biol. Chem. pmid:12364326
Rogers A et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. 2002 J. Clin. Endocrinol. Metab. pmid:12364420
Romas E et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. 2002 Am. J. Pathol. pmid:12368214
Standal T et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. 2002 Blood pmid:12351414
Yang SY et al. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. 2002 Arthritis Rheum. pmid:12355500
Suda T et al. [Merger of bone biology and immunology]. 2002 Tanpakushitsu Kakusan Koso pmid:12385106
Biskobing DM et al. Novel therapeutic options for osteoporosis. 2002 Curr Opin Rheumatol pmid:12118183
Nagasawa T et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. 2002 Clin. Exp. Immunol. pmid:12390325
Mizukami J et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. 2002 Mol. Cell. Biol. pmid:11809792
Wynne F et al. Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. 2002 Calcif. Tissue Int. pmid:12073153
Lubberts E et al. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. 2002 Arthritis Rheum. pmid:12428250
Crotti TN et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. 2002 Ann. Rheum. Dis. pmid:12429533
Hofbauer LC and Schoppet M Osteoprotegerin deficiency and juvenile Paget's disease. 2002 N. Engl. J. Med. pmid:12432053
Jono S et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. 2002 Circulation pmid:12208791
Sedger LM et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. 2002 Eur. J. Immunol. pmid:12209637
Hofbauer LC et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. 2002 J. Cell. Biochem. pmid:12210731
Kondo H et al. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. 2002 J. Bone Miner. Res. pmid:12211438
Hofbauer LC and Schoppet M Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. 2002 J. Clin. Endocrinol. Metab. pmid:12213849
Arko B et al. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. 2002 J. Clin. Endocrinol. Metab. pmid:12213850
Rubin J et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. 2002 J. Clin. Endocrinol. Metab. pmid:12213884
Palmqvist P et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. 2002 J. Immunol. pmid:12218157
Cremer I et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. 2002 Blood pmid:12393586
Giuliani N et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. 2002 Blood pmid:12393684
Liao EY et al. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. 2002 J. Endocrinol. Invest. pmid:12398237
Takahashi E et al. High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. 2002 J. Med. Dent. Sci. pmid:12641381
Stajszczyk M [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. 2002 Pol. Arch. Med. Wewn. pmid:12600190
Fahrleitner A et al. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. 2002 Wien. Klin. Wochenschr. pmid:12602117
Theill LE et al. RANK-L and RANK: T cells, bone loss, and mammalian evolution. 2002 Annu. Rev. Immunol. pmid:11861618
Roux S et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. 2002 Am. J. Clin. Pathol. pmid:11863217
Green EA et al. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. 2002 Immunity pmid:11869680
Holen I et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. 2002 Cancer Res. pmid:11912131
Mori H et al. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. 2002 Histochem. Cell Biol. pmid:11914926
Scatena M and Giachelli C The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. 2002 Trends Cardiovasc. Med. pmid:11852256
Hofbauer LC and Kühne CA Cytokine inhibition: a new therapeutic avenue for skeletal diseases. 2002 Drug Discov. Today pmid:11854049
Kazama JJ et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. 2002 Nephrol. Dial. Transplant. pmid:12271009
Lee SW et al. TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. 2002 J. Biochem. Mol. Biol. pmid:12296995
Oshiro T et al. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. 2002 Anat. Rec. pmid:11920384
Redlich K et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. 2002 Arthritis Rheum. pmid:11920416
Cho CH and Nuttall ME Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. 2002 Expert Opin. Ther. Targets pmid:12472380
Hasegawa T et al. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. 2002 J. Periodont. Res. pmid:12472833
Yamashita T et al. Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. 2002 Endocrinology pmid:12446599
Yang X et al. Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. 2002 Biochem. Biophys. Res. Commun. pmid:11779130
Nosaka K et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. 2002 Blood pmid:11781248
Takayanagi H [Cross-talk between immune and skeletal systems]. 2002 Nippon Rinsho pmid:12510352
Shimizu-Ishiura M et al. Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. 2002 J Electron Microsc (Tokyo) pmid:12455916
Mochizuki S et al. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. 2002 J. Bone Miner. Metab. pmid:11810411
Avbersek-Luznik I et al. Increased levels of osteoprotegerin in hemodialysis patients. 2002 Clin. Chem. Lab. Med. pmid:12476941
Childs LM et al. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. 2002 J. Bone Miner. Res. pmid:11811549
Buckley KA et al. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. 2002 Bone pmid:12477572
Holloway WR et al. Leptin inhibits osteoclast generation. 2002 J. Bone Miner. Res. pmid:11811550
McCauley LK and Nohutcu RM Mediators of periodontal osseous destruction and remodeling: principles and implications for diagnosis and therapy. 2002 J. Periodontol. pmid:12479643
Coen G et al. Serum osteoprotegerin and renal osteodystrophy. 2002 Nephrol. Dial. Transplant. pmid:11812872
Bolon B et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. 2002 Arthritis Rheum. pmid:12483715
Golmia RP et al. Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacós et al. 2002 Arthritis Rheum. pmid:12483748
Whyte MP and Hughes AE Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. 2002 J. Bone Miner. Res. pmid:11771666

Table of Content